Rezolute Q3 FY2026 net loss $16.2M, cash $120.3M; Phase 3 sunRIZE shows >50% hypoglycemia reduction

Rezolute, Inc.

• Net loss $16.2M vs $18.9M YoY; R&D expense $11.4M, down from $15.3M.
• Cash and investments $120.3M at Mar 31, 2026, down from $167.9M at Jun 30, 2025.
• Phase 3 sunRIZE: ersodetug reduced time in hypoglycemia by >50% (FAS) and 60-80% (PPS) vs placebo.
• FDA Type B meeting in March 2026 acknowledged congenital HI challenges; Rezolute to submit comprehensive datasets.
• Tumor HI Phase 3 upLIFT trial enrolling; topline results expected H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.